We are live on ! Find out more
BIOTU

Biotech Acquisition Company Unit

Delisted

BIOTU was delisted on the 2nd of February, 2023.

15 hedge funds and large institutions have $5.18M invested in Biotech Acquisition Company Unit in 2021 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

56% less funds holding

Funds holding: 3415 (-19)

67% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 3

89% less capital invested

Capital invested by funds: $45.2M → $5.18M (-$40M)

90% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 21

Holders
15
Holders Change
-19
Holders Change %
-55.88%
% of All Funds
0.23%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
2
Increased
1
Reduced
3
Closed
21
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Walleye Trading
26
Walleye Trading
New York
-$803K -80,000 Closed
State of Wisconsin Investment Board
27
State of Wisconsin Investment Board
Wisconsin
-$753K -75,000 Closed
YCM
28
Yakira Capital Management
Connecticut
-$540K -53,818 Closed
SSA
29
Schonfeld Strategic Advisors
New York
-$447K -44,498 Closed
Royal Bank of Canada
30
Royal Bank of Canada
Ontario, Canada
-$276K -27,493 Closed
GCIA
31
Gabelli & Co Investment Advisers
New York
-$255K -25,400 Closed
GF
32
Gabelli Funds
New York
-$247K -24,600 Closed
DIG
33
DeepCurrents Investment Group
New York
-$178K -17,730 Closed
VF
34
Virtu Financial
New York
-$169K -16,804 Closed
BFM
35
Boothbay Fund Management
New York
-$151K -15,030 Closed
BI
36
Bulldog Investors
New Jersey
-$140K -13,957 Closed

BIOTU Hedge Fund Activity: Q4 2021 in Review

15 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Biotech Acquisition Company Unit (BIOTU) for Q4 2021, worth a combined $5.18M — down 89% from $45.2M a quarter earlier.

Sellers outnumbered buyers: 21 funds closed out of BIOTU and 2 opened new positions — a net loss of 19 holders — while 3 trimmed existing stakes and 1 added.

The largest buyer was SkyView Investment Advisors, opening a new position worth an estimated $32.2K. The largest seller was Aristeia Capital, exiting entirely with an estimated $11.5M sold.

  • 15 institutional investors held Biotech Acquisition Company Unit (BIOTU) as of Q4 2021, down from 34 in Q3 2021.
  • Funds reported $5.18M of Biotech Acquisition Company Unit stock for Q4 2021, down 89% quarter-over-quarter.
  • 2 funds opened new Biotech Acquisition Company Unit positions in Q4 2021 and 21 closed out, a net change of -19 holders.
  • The largest Biotech Acquisition Company Unit buyer in Q4 2021 was SkyView Investment Advisors, an estimated $32.2K added.
  • The largest Biotech Acquisition Company Unit seller in Q4 2021 was Aristeia Capital, an estimated $11.5M sold.

Based on aggregated 13F filings for Q4 2021.